[go: up one dir, main page]

WO2002015884A3 - Preparation orale a desintegration rapide d'un inhibiteur de la cyclooxygenase-2 - Google Patents

Preparation orale a desintegration rapide d'un inhibiteur de la cyclooxygenase-2 Download PDF

Info

Publication number
WO2002015884A3
WO2002015884A3 PCT/US2001/025762 US0125762W WO0215884A3 WO 2002015884 A3 WO2002015884 A3 WO 2002015884A3 US 0125762 W US0125762 W US 0125762W WO 0215884 A3 WO0215884 A3 WO 0215884A3
Authority
WO
WIPO (PCT)
Prior art keywords
molded article
cyclooxygenase
inhibitor
oral formulation
rapidly disintegrating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/025762
Other languages
English (en)
Other versions
WO2002015884A2 (fr
Inventor
Tugrul T Kararli
Mark J Kontny
Trang T Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60120710T priority Critical patent/DE60120710T2/de
Priority to CA002419592A priority patent/CA2419592A1/fr
Priority to MXPA03001407A priority patent/MXPA03001407A/es
Priority to EP01964122A priority patent/EP1309315B1/fr
Priority to NZ524124A priority patent/NZ524124A/en
Priority to AU2001285011A priority patent/AU2001285011A1/en
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to JP2002520806A priority patent/JP2004506680A/ja
Publication of WO2002015884A2 publication Critical patent/WO2002015884A2/fr
Publication of WO2002015884A3 publication Critical patent/WO2002015884A3/fr
Anticipated expiration legal-status Critical
Priority to CY20061101232T priority patent/CY1105319T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Cette invention concerne un article moulé, tel qu'un comprimé, à administration par voie orale pour le traitement ou la prévention d'états, de troubles ou de maladies induits par la cyclooxygénase-2. Cet article moulé comprend un mélange d'une dose thérapeutiquement efficace d'un médicament inhibiteur sélectif de la cyclooxygénase-2 et d'un système d'excipient acceptable au plan pharmaceutique, composé majoritairement d'un ou de plusieurs hydrates de carbone. Les ingrédients et les doses utilisés pour l'article moulé et le procédé de fabrication dudit article sont choisis de telle sorte que ledit article se désintègre rapidement dans la cavité buccale, la fabrication ne faisant par ailleurs pas intervenir de procédé de granulation par voie humide.
PCT/US2001/025762 2000-08-18 2001-08-17 Preparation orale a desintegration rapide d'un inhibiteur de la cyclooxygenase-2 Ceased WO2002015884A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002419592A CA2419592A1 (fr) 2000-08-18 2001-08-17 Preparation orale a desintegration rapide d'un inhibiteur de la cyclooxygenase-2
MXPA03001407A MXPA03001407A (es) 2000-08-18 2001-08-17 Formulacion oral de desintegracion rapida de un inhibidor de ciclooxigenasa-2.
EP01964122A EP1309315B1 (fr) 2000-08-18 2001-08-17 Preparation orale a desintegration rapide de valdecoxib
NZ524124A NZ524124A (en) 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
AU2001285011A AU2001285011A1 (en) 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
DE60120710T DE60120710T2 (de) 2000-08-18 2001-08-17 Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
JP2002520806A JP2004506680A (ja) 2000-08-18 2001-08-17 シクロオキシゲナーゼ−２阻害剤の迅速崩壊経口製剤
CY20061101232T CY1105319T1 (el) 2000-08-18 2006-08-30 Ταχεως αποσαθρουμενη απο του στοματος συνταγοποιηση του valdecoxib

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22648700P 2000-08-18 2000-08-18
US60/226,487 2000-08-18

Publications (2)

Publication Number Publication Date
WO2002015884A2 WO2002015884A2 (fr) 2002-02-28
WO2002015884A3 true WO2002015884A3 (fr) 2002-07-25

Family

ID=22849097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025762 Ceased WO2002015884A2 (fr) 2000-08-18 2001-08-17 Preparation orale a desintegration rapide d'un inhibiteur de la cyclooxygenase-2

Country Status (14)

Country Link
US (1) US20020071857A1 (fr)
EP (1) EP1309315B1 (fr)
JP (1) JP2004506680A (fr)
AT (1) ATE329583T1 (fr)
AU (1) AU2001285011A1 (fr)
CA (1) CA2419592A1 (fr)
CY (1) CY1105319T1 (fr)
DE (1) DE60120710T2 (fr)
DK (1) DK1309315T3 (fr)
ES (1) ES2265439T3 (fr)
MX (1) MXPA03001407A (fr)
NZ (1) NZ524124A (fr)
PT (1) PT1309315E (fr)
WO (1) WO2002015884A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA13060A (en) * 2001-09-26 2006-11-10 Pharmacia Corp Organoleptically acceptable intraorally disintegrating compositions.
MXPA04003404A (es) * 2001-10-10 2004-06-18 Pharmacia Corp Composiciones de valdecoxib de disgregacion intraoral preparadas mediante un procedimiento de desecacion por pulverizacion.
WO2003049720A1 (fr) * 2001-12-07 2003-06-19 Merck & Co., Inc. Therapie combinee comprenant un inhibiteur de cyclo-oxygenase 2
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AU2003267231A1 (en) * 2002-09-20 2004-04-08 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
CA2524806C (fr) * 2003-05-07 2011-07-12 Akina, Inc. Granules a teneur elevee en plastique, destines a la fabrication de comprimes a dissolution rapide
BRPI0302736B8 (pt) * 2003-06-02 2021-05-25 Ems S/A composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
EP1832288B1 (fr) * 2004-12-27 2012-06-20 Astellas Pharma Inc. Préparation pharmaceutique granulaire stable de solifénacine ou de son sel
GB2423710A (en) * 2005-03-01 2006-09-06 Boots Healthcare Int Ltd Lozenge production process
HRP20100674T1 (hr) * 2005-03-07 2011-01-31 Bayer Schering Pharma Aktiengesellschaft Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka
CN101222911A (zh) * 2005-07-15 2008-07-16 特瓦制药工业有限公司 新的制粒方法及由此制备的颗粒
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
CA2704929C (fr) * 2007-08-07 2018-05-15 Pamela Palmer Compositions et procedes de sedation et d'analgesie procedurales utilisant les formes posologiques transmucosales orales
EP2222282A1 (fr) * 2007-11-15 2010-09-01 Pfizer Products Inc. Formes galéniques comprenant du célécoxib permettant un soulagement de la douleur à la fois rapide et prolongé
WO2009148442A1 (fr) 2008-06-04 2009-12-10 Colgate-Palmolive Company Instrument de soin buccal avec système de cavitation
US20100075930A1 (en) * 2008-09-03 2010-03-25 Yoel Ovil Salicylic salt compositions and related method of treatment of cardiac conditions
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
CN104955330A (zh) * 2012-09-13 2015-09-30 Cba制药有限公司 粉防己碱药物制剂及方法
BR112017013311B1 (pt) 2014-12-23 2022-05-31 Acelrx Pharmaceuticals, Inc Aparelho para a dispensação de formas de dosagem via oral e transmucosal
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
WO2019143432A1 (fr) * 2018-01-21 2019-07-25 Kastner Bernie D Préparation et méthode pour le traitement de la migraine

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396335A1 (fr) * 1989-04-28 1990-11-07 Beecham Group p.l.c. Formulation pharmaceutique
US5501861A (en) * 1992-01-29 1996-03-26 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
EP0748628A2 (fr) * 1995-06-13 1996-12-18 American Home Products Corporation Compositions orales contenant de l'S(+)-étodolac
WO1997044028A1 (fr) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions pour traitement journalier monodose de maladies a mediateur cyclooxygenase-2
WO1999004765A2 (fr) * 1997-07-23 1999-02-04 Chiesi Farmaceutici S.P.A. Compositions pharmaceutiques contenant un couple acide-base effervescent
WO1999047172A2 (fr) * 1998-03-13 1999-09-23 Recordati S.A. Chemical And Pharmaceutical Company Compositions pharmaceutiques orales a prendre sans liquides et contenant des composes d'inclusion
WO2000027382A2 (fr) * 1998-11-12 2000-05-18 Merck & Co., Inc. Combinaison d'un agoniste inverse de gabaa α5 et d'un inhibiteur de cox-2, d'un anti-inflammatoire non steroidien, d'un oestrogene et de vitamine e
WO2000032189A1 (fr) * 1998-11-30 2000-06-08 G. D. Searle & Co. Compositions a base de celecoxib
WO2001039749A2 (fr) * 1999-11-30 2001-06-07 Panacea Biotec Limited Composition a dissolution rapide et a gout sucre de longue duree

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2109509C1 (ru) * 1991-12-24 1998-04-27 Яманути Фармасьютикал Ко., Лтд. Композиция для буккального введения лекарственного средства и способ ее получения
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396335A1 (fr) * 1989-04-28 1990-11-07 Beecham Group p.l.c. Formulation pharmaceutique
US5501861A (en) * 1992-01-29 1996-03-26 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
EP0748628A2 (fr) * 1995-06-13 1996-12-18 American Home Products Corporation Compositions orales contenant de l'S(+)-étodolac
WO1997044028A1 (fr) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions pour traitement journalier monodose de maladies a mediateur cyclooxygenase-2
WO1999004765A2 (fr) * 1997-07-23 1999-02-04 Chiesi Farmaceutici S.P.A. Compositions pharmaceutiques contenant un couple acide-base effervescent
WO1999047172A2 (fr) * 1998-03-13 1999-09-23 Recordati S.A. Chemical And Pharmaceutical Company Compositions pharmaceutiques orales a prendre sans liquides et contenant des composes d'inclusion
WO2000027382A2 (fr) * 1998-11-12 2000-05-18 Merck & Co., Inc. Combinaison d'un agoniste inverse de gabaa α5 et d'un inhibiteur de cox-2, d'un anti-inflammatoire non steroidien, d'un oestrogene et de vitamine e
WO2000032189A1 (fr) * 1998-11-30 2000-06-08 G. D. Searle & Co. Compositions a base de celecoxib
WO2001039749A2 (fr) * 1999-11-30 2001-06-07 Panacea Biotec Limited Composition a dissolution rapide et a gout sucre de longue duree

Also Published As

Publication number Publication date
DK1309315T3 (da) 2006-10-09
JP2004506680A (ja) 2004-03-04
MXPA03001407A (es) 2003-06-06
DE60120710T2 (de) 2007-06-14
ES2265439T3 (es) 2007-02-16
NZ524124A (en) 2004-09-24
EP1309315B1 (fr) 2006-06-14
AU2001285011A1 (en) 2002-03-04
CA2419592A1 (fr) 2002-02-28
US20020071857A1 (en) 2002-06-13
ATE329583T1 (de) 2006-07-15
PT1309315E (pt) 2006-09-29
CY1105319T1 (el) 2010-03-03
DE60120710D1 (de) 2006-07-27
WO2002015884A2 (fr) 2002-02-28
EP1309315A2 (fr) 2003-05-14

Similar Documents

Publication Publication Date Title
WO2002015884A3 (fr) Preparation orale a desintegration rapide d'un inhibiteur de la cyclooxygenase-2
MY128368A (en) Method for producing quickly decomposable solid pharmaceutical preparations
EP1120109A3 (fr) Formes posologiques solides à désintégration et dissolution rapide
AU2003218641A1 (en) Pharmaceutical dosage form and method for the production thereof
WO2008120548A3 (fr) Comprimé à désintégration orale
MY121669A (en) Fast-dissolving galanthamine hydrobromide tablet
PL341466A1 (en) Instantaneously spreading dised pharmacological preparation and method of forming granules
NZ734446A (en) Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor
HUP0101282A1 (hu) Szájüregben gyorsan széteső tabletta, és eljárás annak előállítására
CA2990445A1 (fr) Melange thermocinetique pour des applications pharmaceutiques
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
WO2003047519A3 (fr) Composition pharmaceutique pour comprime annulaire compresse et comprime triture moule pour administration intra-orale et par voie buccale
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
MX9308188A (es) Glucomanano de konjac facilmente disponible, como un excipiente de liberacion sostenida.
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
ZA975827B (en) Stable medicament with benzimidazole derivatives as an active ingredient for oral administration and method for its production.
WO2008142572A3 (fr) Formulation de comprimé à libération contrôlée contenant de l'aluminométasilicate de magnésium
WO2001043747A8 (fr) Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
WO2003082241A3 (fr) Formulations de clarithromycine dotees d'une biodisponibilite amelioree
WO2004071374A3 (fr) Compositions pharmaceutiques d'administration orale une fois par jour
WO2002092056A8 (fr) Procede de compactage destine a la fabrication d'une forme posologique a base de phenytoine de sodium
WO2001026621A3 (fr) Nouvelle formulation de mirtazapine
CN1903208B (zh) 阿德福韦酯口崩片的制备方法
WO2010019279A8 (fr) Compositions pharmaceutiques configurées pour dissuader le fractionnement des formes posologiques
WO2002041897A3 (fr) Compositions pharmaceutiques a action antidiabetique constitues de l'association d'un biguanide et d'un sulfonamide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001285011

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001964122

Country of ref document: EP

Ref document number: 524124

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2419592

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001407

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002520806

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001964122

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 524124

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524124

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001964122

Country of ref document: EP